Jeff Bird focuses on healthcare, including biotechnology and medical devices.

He is currently a board member at Verinata Health (noninvasive prenatal diagnosis), Drais Pharmaceuticals (oncology therapeutics), Horizon Pharma, Inc. (novel fixed dose drug combinations), NuGen Technologies (research reagents), Portola Pharmaceuticals (a spin-out of Cor/Millennium focused on cardiovascular therapeutics), Restoration Robotics (aesthetic surgery devices), Threshold Pharmaceuticals (oncology therapeutics, NASDAQ: THLD), and ViroBay, Inc. (pain and inflammatory therapeutics). He also represents the firm’s investments in Acceleron Pharmaceuticals (metabolic therapeutics), Ameritox (pain therapeutic drug monitoring), Barrx (gastrointestinal devices), and Pacific Biosciences (DNA sequencing).

Jeff was formerly a director at Akarx Inc., (acquired by MGI Pharma in 2008), Idun Pharmaceuticals, (acquired by Pfizer in 2005), Roxro Pharma (acquired by Daiichi-Sankyo in 2010), and Xoft, Inc. (acquired by iCAD in 2010).

Jeff was previously Senior Vice President, Business Operations at Gilead Sciences, where he worked from 1988 to 1990 and then 1992 to 2000. He was primarily responsible for several alliances with major pharmaceutical companies and helped Gilead to acquire NeXstar in a $550 million transaction. His commercial responsibilities included direct sales in the US and Europe.

Jeff received a degree in Biological Sciences from Stanford in 1982, a Ph.D. in Cancer Biology in 1988 and a M.D. in 1992 from Stanford Medical School.